1
|
Chen W, Ding Y, Lu J, Shi Y, Gao Y, Peng C. Efficacy and survival of infliximab in psoriasis patients: A single-center experience in China. Dermatol Ther 2020; 33:e14227. [PMID: 32844504 DOI: 10.1111/dth.14227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Revised: 08/16/2020] [Accepted: 08/18/2020] [Indexed: 11/28/2022]
Abstract
Psoriasis is a chronic, systemic disease that requires long-term management. Biologic agents have been used widely against psoriasis, such as infliximab. We analyzed the survival and discontinuation rates of infliximab when treating psoriasis under real-world conditions in China. Patients with moderate-to-severe psoriasis treated with infliximab in Shanghai Skin Disease Hospital from January 2015 to April 2020 were included in our retrospective study. Information from their medical records (clinical characteristics, Psoriasis Area Severity Index [PASI] score, laboratory results, and time of discontinuation) was collected through the Shanghai Skin Disease Hospital database. The survival of infliximab was assessed with Kaplan-Meier plots and multivariate Cox regression. Forty-two patients who underwent treatment were assessed retrospectively (38.1% had been diagnosed with psoriatic arthritis [PsA]). The discontinuation rate was 57.1%, the mean survival time of discontinuation was 57 weeks for patients with PsA vs 69 weeks for those without PsA (P = .5993). The cholesterol level (P = .003) and lymphocyte percentage (P = .010) were associated with longer survival of infliximab according to Cox regression analysis. Our study revealed that infliximab had a similar drug survival as previous studies, the high cholesterol level and lymphocyte percentage might function as negative predictor for infliximab persistence.
Collapse
Affiliation(s)
- Wenjuan Chen
- Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.,Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China
| | - Yangfeng Ding
- Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.,Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China
| | - Jiajing Lu
- Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.,Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China
| | - Yuling Shi
- Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.,Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China
| | - Yunlu Gao
- Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.,Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China
| | - Chen Peng
- Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.,Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China
| |
Collapse
|
2
|
Colls-Gonzalez M, Notario-Rosa J, Bas-Minguet J, Padullés-Zamora A, Morandeira-Rego F, Valentí-Medina F, Colom-Codina H, Padullés-Zamora N. Association between infliximab concentrations and clinical response in psoriasis: a prospective cohort study. J DERMATOL TREAT 2019; 32:180-187. [PMID: 31696747 DOI: 10.1080/09546634.2019.1690623] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
BACKGROUND Infliximab (IFX) trough concentrations (Cmin) have been linked to treatment efficacy in psoriatic patients. Inter-individual IFX Cmin variability and factors influencing IFX pharmacokinetics could explain differences in treatment response. OBJECTIVE To evaluate the association between IFX Cmin and clinical outcomes in psoriatic patients. METHODS Prospective study of 33 patients with moderate to severe psoriasis receiving IFX at Bellvitge University Hospital, between October 2013 and November 2016. IFX Cmin and antibodies toward infliximab (ATI) were measured. RESULTS We collected 155 IFX Cmin and ATI values (mean age, 46 (14) years; 11 (33.3%) women). Mean IFX Cmin was 2.5 (2.4) mg/L and ATIs were detected in six patients, resulting in undetectable IFX Cmin. IFX Cmin was significantly associated with ATI and body mass index (BMI) (β -2.51, 95% CI -3.56 to -1.4 and β -0.05, 95% CI -0.09 to -0.01). PASI score and PASI 90/100 response were significantly associated with IFX Cmin (IRR 0.80, 95% CI 0.70 to 0.92; OR 1.79, 95% CI 1.18 to 2.71 and OR 1.79, 95% CI 1.14 to 2.81). CONCLUSION IFX Cmin significantly influences PASI 90/100 response rates. IFX Cmin wa significantly associated with ATI and BMI. The observed inter-individual variability in IFX Cmin supports the need for IFX drug monitoring.
Collapse
Affiliation(s)
- M Colls-Gonzalez
- Department of Pharmacy, Hospital Universitari de Bellvitge, Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology Program, Institut D'Investigació Biomèdica de Bellvitge - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - J Notario-Rosa
- Department of Dermatology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | - J Bas-Minguet
- Department of Immunology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | - A Padullés-Zamora
- Department of Pharmacy, Hospital Universitari de Bellvitge, Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology Program, Institut D'Investigació Biomèdica de Bellvitge - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - F Morandeira-Rego
- Department of Immunology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | - F Valentí-Medina
- Department of Dermatology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | - H Colom-Codina
- Pharmacy and Pharmaceutical Technology Department, School of Pharmacy, Universitat de Barcelona - UB, Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology Program, Institut D'Investigació Biomèdica de Bellvitge - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - N Padullés-Zamora
- Department of Pharmacy, Hospital Universitari de Bellvitge, Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology Program, Institut D'Investigació Biomèdica de Bellvitge - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
3
|
Hirt PA, Castillo DE, Yosipovitch G, Keri JE. Skin changes in the obese patient. J Am Acad Dermatol 2019; 81:1037-1057. [DOI: 10.1016/j.jaad.2018.12.070] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2018] [Revised: 12/17/2018] [Accepted: 12/18/2018] [Indexed: 12/31/2022]
|
4
|
Kromer C, Wilsmann-Theis D, Gerdes S, Philipp S, Schaarschmidt ML, Schmieder A, Dakna M, Arnold T, Peitsch WK, Mössner R. Drug Survival und Gründe für einen Therapieabbruch bei Pustulosis palmoplantaris: Eine retrospektive multizentrische Studie. J Dtsch Dermatol Ges 2019; 17:503-517. [PMID: 31115984 DOI: 10.1111/ddg.13834_g] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2018] [Accepted: 11/19/2018] [Indexed: 12/16/2022]
Affiliation(s)
- Christian Kromer
- Klinik für Dermatologie, Venerologie und Allergologie, Georg-August-Universität Göttingen
| | | | - Sascha Gerdes
- Psoriasis-Zentrum in der Hautklinik des Universitätsklinikums Schleswig-Holstein, Campus Kiel
| | - Sandra Philipp
- Klinik für Dermatologie, Venerologie und Allergologie, Charité - Universitätsmedizin Berlin
| | | | - Astrid Schmieder
- Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Mannheim
| | - Mohammed Dakna
- Institut für Medizinische Statistik, Georg-August-Universität Göttingen
| | - Tobias Arnold
- Abteilung für Pneumologie, Theresienkrankenhaus, Mannheim
| | | | - Rotraut Mössner
- Klinik für Dermatologie, Venerologie und Allergologie, Georg-August-Universität Göttingen
| |
Collapse
|
5
|
Kromer C, Wilsmann‐Theis D, Gerdes S, Philipp S, Schaarschmidt M, Schmieder A, Dakna M, Arnold T, Peitsch WK, Mössner R. Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study. J Dtsch Dermatol Ges 2019; 17:503-516. [PMID: 30994260 PMCID: PMC6850581 DOI: 10.1111/ddg.13834] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2018] [Accepted: 11/19/2018] [Indexed: 01/30/2023]
Abstract
BACKGROUND Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease-related to psoriasis. Its treatment is challenging, and little is known about the sustainability of different medications. The aim of this study was to analyze drug survival rates and drug discontinuation in the treatment of PPP under real-world conditions. PATIENTS AND METHODS Patients with PPP treated in the dermatology departments of five German university medical centers between 01/2005 and 08/2017 were included in our retrospective study. Drug survival of systemic therapies was assessed with Kaplan-Meier analysis and multivariate regression. RESULTS Overall, 347 patients with 935 treatment courses were identified. Within the group of non-biologic systemic agents, apremilast showed the highest median drug survival (15 months), followed by cyclosporine (12 months), the combination of acitretin and topical PUVA (9 months), MTX (8 months), acitretin monotherapy (6 months), alitretinoin (5 months), and fumaric acid esters (3 months). Among biologicals, the highest maintenance rate was detected for certolizumab pegol (restricted mean: 47.4 months), followed by infliximab (median: 26 months), golimumab (22 months), ustekinumab (21 months), adalimumab (18 months), secukinumab (9 months), and etanercept (8 months). CONCLUSIONS Biologicals and apremilast may serve as second-line options for treatment of PPP and should be further evaluated.
Collapse
Affiliation(s)
- Christian Kromer
- Department of DermatologyGeorg‐August‐University GöttingenGöttingenGermany
| | | | - Sascha Gerdes
- Psoriasis‐CenterDepartment of DermatologyUniversity Hospital Schleswig‐HolsteinCampus KielKielGermany
| | - Sandra Philipp
- Department of DermatologyCharité – Universitätsmedizin BerlinBerlinGermany
| | | | - Astrid Schmieder
- Department of DermatologyUniversity Medical Center MannheimMannheimGermany
| | - Mohammed Dakna
- Department of Medical StatisticsGeorg‐ August‐University GoettingenGoettingenGermany
| | - Tobias Arnold
- Department of PneumologyTheresienkrankenhausMannheimGermany
| | | | - Rotraut Mössner
- Department of DermatologyGeorg‐August‐University GöttingenGöttingenGermany
| |
Collapse
|
6
|
Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep 2018; 8:16068. [PMID: 30375427 PMCID: PMC6207685 DOI: 10.1038/s41598-018-34293-y] [Citation(s) in RCA: 62] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2018] [Accepted: 10/16/2018] [Indexed: 02/08/2023] Open
Abstract
Drug survival of biologics represents their real-world effectiveness and safety. We conducted a meta-analysis of real-world evidence on the drug survival of biologics in treating psoriasis. We searched the PubMed, CENTRAL, and EMBASE databases from inception to 7th October 2017 for studies reporting the annual drug survival for at least 1 year. Two authors independently screened and selected relevant studies, and assessed their risk of bias. A third author was available for arbitrating discrepancies. We conducted a random-effects model meta-analysis to obtain the respective pooled drug survival from year 1 to 4. We conducted subgroup analysis on biologic-naïve subjects, discontinuation for loss of efficacy and adverse effects. We included 37 studies with 32,631 subjects. The drug survival for all biologics decreased with time, dropping from 66% at year 1 to 41% at year 4 for etanercept, from 69% to 47% for adalimumab, from 61% to 42% for infliximab, and from 82% to 56% for ustekinumab. Ustekinumab was associated with the highest drug survival in all and biologic-naïve subjects. Etanercept was associated with the lowest drug survival and was most commonly discontinued for loss of efficacy. Infliximab was most frequently associated with discontinuation for adverse effects. Clinicians may use this study as a reference in treating psoriasis.
Collapse
Affiliation(s)
- Pei-Tzu Lin
- Department of Pharmacy, Chang Gung Memorial Hospital, Chiayi, Chiayi, Taiwan.,Department of Nursing, Chang Gung University of Science and Technology, Chiayi, Taiwan
| | - Shu-Hui Wang
- Department of Dermatology, Far Eastern Memorial Hospital, New Taipei, Taiwan.,Graduate Institute of Applied Science and Engineering, College of Science and Engineering, Fu Jen Catholic University, New Taipei, Taiwan
| | - Ching-Chi Chi
- Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan. .,College of Medicine, Chang Gung University, Taoyuan, Taiwan.
| |
Collapse
|
7
|
Costanzo A, Malara G, Pelucchi C, Fatiga F, Barbera G, Franchi A, Galeone C. Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival. Dermatology 2018; 234:1-12. [DOI: 10.1159/000488586] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2017] [Accepted: 03/17/2018] [Indexed: 12/26/2022] Open
|
8
|
Petridis A, Panagakis P, Moustou E, Vergou T, Kallidis P, Mandekou-Lefaki I, Chaidemenos G, Sotiriadis D, Alexopoulou G, Haratsis Y, Antoniou C. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in. J Eur Acad Dermatol Venereol 2018; 32:768-775. [DOI: 10.1111/jdv.14802] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2017] [Accepted: 01/03/2018] [Indexed: 11/29/2022]
Affiliation(s)
- A. Petridis
- State Dermatology Clinic; A. Syggros Hospital of Venereal and Skin Diseases; Athens Greece
| | - P. Panagakis
- State Dermatology Clinic; A. Syggros Hospital of Venereal and Skin Diseases; Athens Greece
| | - E. Moustou
- 1st Department of Dermatology; A. Syggros Hospital; University of Athens; Athens Greece
| | - T. Vergou
- 1st Department of Dermatology; A. Syggros Hospital; University of Athens; Athens Greece
| | - P. Kallidis
- General Hospital of Giannitsa; Giannitsa Greece
| | - I. Mandekou-Lefaki
- State Dermatology Clinic; Hospital of Skin and Venereal Diseases of Thessaloniki; Thessaloniki Greece
| | | | - D. Sotiriadis
- Department of Dermatology; General Hospital of Thessaloniki Papageorgiou; Thessaloniki Greece
| | | | | | - C. Antoniou
- 1st Department of Dermatology; A. Syggros Hospital; University of Athens; Athens Greece
| |
Collapse
|
9
|
Sherman S, Hodak E, Pavlovsky L. Can etanercept treatment failure in moderate-to-severe psoriasis be overcome by addition of low-dose methotrexate? A single-center experience. J DERMATOL TREAT 2018; 29:666-670. [PMID: 29466892 DOI: 10.1080/09546634.2018.1441491] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Loss of efficacy is a major anticipated shortcoming of utilizing etanercept and other biologic agents for treating moderate-to-severe psoriasis. PURPOSE To investigate the addition of low-dose methotrexate as a means to increase etanercept drug survival. METHODS Eleven patients with severe psoriasis were switched to a combination of etanercept with low-dose methotrexate therapy, after a primary or secondary failure with etanercept treatment as a monotherapy. Time period for cessation of combined treatment and side effects were documented. The effect of previous methotrexate treatment was investigated. RESULTS Six men and five women were included in the study. The patients had moderate-to-severe psoriasis with a mean baseline Psoriasis Area and Severity Index (PASI) of 29 (median 25). Median duration of etanercept monotherapy was 12 months. Median duration of combined treatment was 13 months. Combined treatment was discontinued in three patients due to side effects. Previous failure of methotrexate monotherapy did not alter the duration of the combined treatment. CONCLUSION Addition of low-dose methotrexate may rescue etanercept therapy after failure of etanercept monotherapy in patients with moderate-to-severe psoriasis.
Collapse
Affiliation(s)
- Shany Sherman
- a Department of Dermatology , Rabin Medical Center-Beilinson Hospital , Petach Tikva , Israel
| | - Emmilia Hodak
- a Department of Dermatology , Rabin Medical Center-Beilinson Hospital , Petach Tikva , Israel.,b Sackler Faculty of Medicine , Tel Aviv University , Tel Aviv , Israel
| | - Lev Pavlovsky
- a Department of Dermatology , Rabin Medical Center-Beilinson Hospital , Petach Tikva , Israel
| |
Collapse
|
10
|
Arnold T, Schaarschmidt ML, Herr R, Fischer JE, Goerdt S, Peitsch WK. Drug survival rates and reasons for drug discontinuation in psoriasis. J Dtsch Dermatol Ges 2018; 14:1089-1099. [PMID: 27879076 DOI: 10.1111/ddg.13152] [Citation(s) in RCA: 47] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Accepted: 06/04/2016] [Indexed: 01/22/2023]
Abstract
BACKGROUND AND OBJECTIVES Moderate-to-severe psoriasis frequently requires long-term systemic therapy. Reflecting efficacy, safety, and treatment satisfaction, drug survival is an indicator of therapeutic success. The objective of the present study was to assess drug survival rates and reasons for discontinuation of fumaric acid esters (FAE), methotrexate (MTX), acitretin (ACI), cyclosporine A (CyA), adalimumab (ADA), etanercept (ETA), infliximab (INF), and ustekinumab (UST) in patients with moderate-to-severe psoriasis. PATIENTS AND METHODS We performed a retrospective analysis of 373 patients who had received a total of 696 treatment courses at a German university hospital in the period 1/2003-5/2014. RESULTS The crude probability of survival was highest for UST, followed by ADA, ETA, INF, FAE, MTX, ACI, and CyA. In multivariate regression analysis using FAE as reference, hazard ratios (HR) for discontinuation were 0.14 (95 % confidence interval: 0.06-0.35) for UST, 0.43 (0.26-0.73) for ADA, 2.11 (1.14-3.91) for ACI, and 3.26 (1.44-7.39) for CyA. INF showed longer survival when combined with MTX (HR 2.87, 1.21-6.81). Traditional systemic antipsoriatic agents as well as INF were most frequently discontinued due to adverse events; all other biologics, due to inefficacy with respect to cutaneous lesions. CONCLUSIONS Drug survival rates should be integrated into therapeutic decisions in order to provide patients with an optimal long-term strategy.
Collapse
Affiliation(s)
- Tobias Arnold
- Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Marthe-Lisa Schaarschmidt
- Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Raphael Herr
- Mannheim Institute of Public Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Joachim E Fischer
- Mannheim Institute of Public Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Sergij Goerdt
- Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Wiebke K Peitsch
- Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.,Department of Dermatology and Phlebology, Vivantes Klinikum im Friedrichshain, Berlin, Germany
| |
Collapse
|
11
|
Abstract
INTRODUCTION Psoriasis has a profound impact on patients' lives, but adherence to topical treatment of psoriasis is still poor. Biologic treatment has revolutionized the management of psoriasis, but adherence to treatment may still be a barrier for some patients. Areas covered: A PubMed search was conducted in August 2017 using the terms 'biologics psoriasis adherence' and 'biologics psoriasis survival.' Additional articles were obtained by perusing the references of articles identified in the original PubMed search. Articles that did not specifically mention 'survival,' 'adherence,' or 'persistence' were not included. We review the measures used to assess adherence to biologics for psoriasis and the factors impacting drug survival and adherence rates for biologics in psoriasis. Expert commentary: Drug survival and adherence rates for biologic therapy is less than ideal but may be modifiable. Means that may improve adherence and drug survival include individualized choice of biologic and providing additional support for patients who are at increased risk for prematurely stopping treatment.
Collapse
Affiliation(s)
- Lauren Seale
- a Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA
| | - Leah A Cardwell
- a Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA
| | - Steven R Feldman
- a Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.,b Department of Pathology , Wake Forest School of Medicine , Winston-Salem , NC , USA.,c Department of Social Sciences & Health Policy , Wake Forest School of Medicine , Winston-Salem , NC , USA
| |
Collapse
|
12
|
Xie KK, Braue A, Martyres R, Varigos G. Baseline patients’ characteristics as predictors for therapeutic survival and response in patients with psoriasis on biological treatments. Australas J Dermatol 2018; 59:e247-e252. [DOI: 10.1111/ajd.12760] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Accepted: 10/21/2017] [Indexed: 01/08/2023]
Affiliation(s)
- Kenneth K Xie
- Faculty of Medicine; Dentistry and Health Sciences; The University of Melbourne; Melbourne Victoria Australia
| | - Anna Braue
- Faculty of Medicine; Dentistry and Health Sciences; The University of Melbourne; Melbourne Victoria Australia
- Department of Dermatology; Royal Melbourne Hospital; Melbourne Victoria Australia
| | - Raymond Martyres
- Faculty of Medicine; Dentistry and Health Sciences; The University of Melbourne; Melbourne Victoria Australia
- Department of Dermatology; Royal Melbourne Hospital; Melbourne Victoria Australia
| | - George Varigos
- Faculty of Medicine; Dentistry and Health Sciences; The University of Melbourne; Melbourne Victoria Australia
- Department of Dermatology; Royal Melbourne Hospital; Melbourne Victoria Australia
| |
Collapse
|
13
|
No DJ, Inkeles MS, Amin M, Wu JJ. Drug survival of biologic treatments in psoriasis: a systematic review. J DERMATOL TREAT 2017; 29:460-466. [PMID: 29076754 DOI: 10.1080/09546634.2017.1398393] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Drug survival measures the length of time until discontinuation of a drug. The length of time a patient remains on a biologic drug is impacted by several factors such as tolerability, side effects, safety profile and effectiveness. To evaluate the long-term drug survival, data of the most commonly prescribed biologic medications used in the treatment of psoriasis, a systematic review was conducted. A literature search using PubMed, the Cochrane Library and the Cumulative Index to Nursing and Allied Health Literature from January 1 2010 to October 28 2016 identified 3734 abstracts. Of which, 36 publications with over 40,000 patients met the inclusion criteria. The median overall drug survival for ustekinumab, adalimumab, infliximab and etanercept was 38.0, 36.5, 26.6 and 24.7 months, respectively. The mean annual drug survival rate of TNF inhibitors was 70%, 57%, 51%, 45% and 41% at years-1, 2, 3, 4 and 5, respectively. The 5-year mean annual drug survival rate of ustekinumab was 87%, 78%, 70%, 71% and 51%, respectively. Based on our findings, ustekinumab appears to have a longer drug survival with lower rates of discontinuation compared to tumor necrosis factor inhibitors.
Collapse
Affiliation(s)
- Daniel J No
- a Dermatology , Loma Linda University School of Medicine , Loma Linda , CA , USA
| | - Megan S Inkeles
- b Internal Medicine , Kaiser Permanente Los Angeles Medical Center , Los Angeles , CA , USA
| | - Mina Amin
- c Dermatology , University of California Riverside School of Medicine , Riverside , CA , USA
| | - Jashin J Wu
- d Department of Dermatology , Kaiser Permanente Los Angeles Medical Center , Los Angeles , CA , USA
| |
Collapse
|
14
|
Rønholt K, Iversen L. Old and New Biological Therapies for Psoriasis. Int J Mol Sci 2017; 18:E2297. [PMID: 29104241 PMCID: PMC5713267 DOI: 10.3390/ijms18112297] [Citation(s) in RCA: 153] [Impact Index Per Article: 21.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2017] [Revised: 10/26/2017] [Accepted: 10/27/2017] [Indexed: 02/07/2023] Open
Abstract
Biological therapy became available for psoriasis with the introduction of alefacept at the beginning of this century. Up to then, systemic treatment options comprised small molecule drugs, targeting the immune system in a non-specific manner. The first biologics targeted T-cell activation and migration and served as an alternative to small molecules. However, significant improvement in outcome was first accomplished with the introduction of tumor necrosis factor-α inhibitors that were already approved for other inflammatory disorders, including rheumatic diseases. Along with the progress in understanding psoriasis pathogenesis, highly targeted and effective therapies have since developed with the perspective not only to improve but to clear psoriasis. These accomplishments enable future achievement of advanced goals to individualize treatment best suited for each patient. Mechanistic studies with patients treated with the new highly targeted biologics may guide us towards these goals. This review offers an overview of biologics developed for psoriasis and illustrate a historical progress in the treatment of this common chronic inflammatory skin condition.
Collapse
Affiliation(s)
- Kirsten Rønholt
- Department of Dermatology, Aarhus University Hospital, 8000 Aarhus, Denmark.
| | - Lars Iversen
- Department of Dermatology, Aarhus University Hospital, 8000 Aarhus, Denmark.
| |
Collapse
|
15
|
Kromer C, Peitsch WK, Herr R, Schmieder A, Sonntag D, Schaarschmidt ML. Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability. J Dtsch Dermatol Ges 2017; 15:189-200. [PMID: 28214326 DOI: 10.1111/ddg.12919] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2015] [Accepted: 11/14/2015] [Indexed: 12/13/2022]
Abstract
BACKGROUND AND OBJECTIVES Treatment satisfaction can be improved by integrating patients' preferences into shared decision-making. We recently investigated patients' preferences for attributes of biologicals, and showed high preferences for safety and efficacy. The objective of the present study was to assess the impact of treatment experience on these preferences. PATIENTS AND METHODS Preferences for outcome (probability of 50 % and 90 % improvement, time until response, sustainability of success, probability of mild and severe adverse events, probability of ACR 20 response) and process attributes (treatment location, frequency, duration, and delivery method) were analyzed in 200 participants with moderate-to-severe psoriasis using conjoint analysis. The impact of current and previous therapies, disease duration, and treatment satisfaction on 'Relative Importance Scores' was determined by analysis of variance, post hoc tests, and multivariate regression. RESULTS Participants presently on topical therapy (p = 0.02) or phototherapy (p = 0.032) placed more importance on treatment duration than others. Individuals who had previously been given traditional systemic agents (p = 0.028) or biologicals (p = 0.044) favored sustainability more than others. With an increasing number of systemic agents ever received (p = 0.045) and longer disease duration (p = 0.018), the latter attribute became increasingly important. CONCLUSIONS Patients' preferences for biologicals vary in correlation with treatment experience and disease duration, aspects to be addressed in the context of shared decision-making.
Collapse
Affiliation(s)
- Christian Kromer
- Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Wiebke K Peitsch
- Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Raphael Herr
- Mannheim Institute of Public Health, Social and Preventive Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Astrid Schmieder
- Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Diana Sonntag
- Mannheim Institute of Public Health, Social and Preventive Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Marthe-Lisa Schaarschmidt
- Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| |
Collapse
|
16
|
Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab. Inflamm Bowel Dis 2017; 23:1853-1859. [PMID: 28837519 DOI: 10.1097/mib.0000000000001179] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Infliximab (IFX) is effective in inducing and maintaining remission in patients with luminal and anoperineal Crohn's disease (CD). However, treatment failure within 12 months after initiating IFX is observed in a significant proportion of patients. The aim of the present study was to determine whether the body mass index (BMI) affects response to IFX during the first year of treatment in patients with CD. METHODS All patients with luminal CD who began IFX between January 2010 and May 2014 were prospectively included. BMI was calculated before IFX treatment was begun, and patients were divided into 3 groups: normal BMI (BMI < 25 kg/m), overweight patients (BMI of 25.0-30 kg/m), and obese patients (BMI > 30.0 kg/m). The primary outcome was to evaluate the rate and delay of IFX optimization during the first year of treatment among normal weight, overweight, and obese patients. RESULTS One hundred forty patients were included. Demographic and clinical characteristics at IFX initiation were comparable among the 3 groups. Within 12 months after the initiation of IFX, the rate of IFX optimization was significantly higher in overweight and obese patients than in the normal BMI group: 52%, 56%, and 20%, respectively (P = 0.0002). The median time until optimization of IFX was significantly shorter in overweight and obese patients than in the normal BMI group: 7, 7, and 10 months, respectively (P = 0.03). A BMI >25 kg/m was significantly associated with IFX optimization within 12 months on multivariate analysis. CONCLUSION This is the first study to show that optimization of IFX is more frequent and faster in obese and overweight patients with CD and occurs within 12 months after beginning IFX, suggesting that an induction regimen with higher doses of IFX and a tight control of IFX concentrations may be needed in these patients.
Collapse
|
17
|
Kromer C, Peitsch WK, Herr R, Schmieder A, Sonntag D, Schaarschmidt M. Behandlungspräferenzen für Biologika bei Psoriasis: erfahrene Patienten legen Wert auf Nachhaltigkeit. J Dtsch Dermatol Ges 2017; 15:189-201. [DOI: 10.1111/ddg.12919_g] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2015] [Accepted: 11/14/2015] [Indexed: 11/29/2022]
Affiliation(s)
- Christian Kromer
- Klinik für Dermatologie, Venerologie und AllergologieUniversitätsmedizin Mannheim, Universität Heidelberg Mannheim
| | - Wiebke K. Peitsch
- Klinik für Dermatologie, Venerologie und AllergologieUniversitätsmedizin Mannheim, Universität Heidelberg Mannheim
| | - Raphael Herr
- Mannheimer Institut für Public Health, Sozial‐ und PräventivmedizinMedizinische Fakultät Mannheim, Universität Heidelberg Mannheim
| | - Astrid Schmieder
- Klinik für Dermatologie, Venerologie und AllergologieUniversitätsmedizin Mannheim, Universität Heidelberg Mannheim
| | - Diana Sonntag
- Mannheimer Institut für Public Health, Sozial‐ und PräventivmedizinMedizinische Fakultät Mannheim, Universität Heidelberg Mannheim
| | - Marthe‐Lisa Schaarschmidt
- Klinik für Dermatologie, Venerologie und AllergologieUniversitätsmedizin Mannheim, Universität Heidelberg Mannheim
| |
Collapse
|
18
|
Torii H, Nakano M, Yano T, Kondo K, Nakagawa H. Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study. J Dermatol 2016; 44:552-559. [PMID: 27882586 PMCID: PMC5434916 DOI: 10.1111/1346-8138.13698] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2016] [Accepted: 10/11/2016] [Indexed: 12/11/2022]
Abstract
Although infliximab is approved for psoriasis, its efficacy is reduced over time in some patients. The aim of this phase III trial is to evaluate efficacy and safety of infliximab dose escalation in Japanese psoriasis patients with loss of efficacy to standard‐dose therapy. Patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis or psoriatic erythroderma who showed loss of efficacy to standard‐dose therapy received infliximab dose escalation (10 mg/kg every 8 weeks) from weeks 0 to 32. Loss of efficacy was defined as not maintaining 50% reduction in the Psoriasis Area and Severity Index (PASI 50) after achieving PASI 75. Efficacy and safety were evaluated up to week 40. Fifty‐one patients received dose escalation and 43 completed the study. PASI 75 and median improvement rate of PASI score at week 40 were 44% and 70.0%, respectively, showing efficacy in skin symptoms. Efficacies in quality of life, nail psoriasis and joint pain were also obtained. Median serum infliximab level increased from less than 0.1 to 1.1 μg/mL from weeks 0 to 40, showing positive correlation between efficacy and serum infliximab level at week 40. Favorable efficacy was observed in patients with detectable serum infliximab levels (≥0.1 μg/mL) at baseline. Incidences of adverse events, serious adverse events, serious infections and serious infusion reactions were 92%, 10%, 4% and 0%, respectively. No marked difference was observed in both efficacy and safety among psoriasis types. No new safety concerns were observed. Infliximab dose escalation was effective and well‐tolerated in psoriasis patients with loss of efficacy to standard‐dose therapy, suggesting that dose escalation may be a useful therapeutic option for these patients.
Collapse
Affiliation(s)
- Hideshi Torii
- Division of Dermatology, Tokyo Yamate Medical Center, Tokyo, Japan
| | - Masayuki Nakano
- Sohyaku Innovative Research Division, Mitsubishi Tanabe Pharma, Tokyo, Japan
| | - Toshiro Yano
- Ikuyaku Integrated Value Developmental Division, Mitsubishi Tanabe Pharma, Osaka, Japan
| | - Kazuoki Kondo
- Sohyaku Innovative Research Division, Mitsubishi Tanabe Pharma, Tokyo, Japan
| | - Hidemi Nakagawa
- Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan
| | | |
Collapse
|
19
|
Arnold T, Schaarschmidt M, Herr R, Fischer JE, Goerdt S, Peitsch WK. „Drug‐Survival“‐Raten und Gründe für den Abbruch von Systemtherapien bei Psoriasis. J Dtsch Dermatol Ges 2016; 14:1090-1101. [DOI: 10.1111/ddg.13152_g] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Accepted: 06/04/2016] [Indexed: 12/29/2022]
Affiliation(s)
- Tobias Arnold
- Klinik für Dermatologie Venerologie und Allergologie Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg Mannheim
| | - Marthe‐Lisa Schaarschmidt
- Klinik für Dermatologie Venerologie und Allergologie Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg Mannheim
| | - Raphael Herr
- Mannheimer Institut für Public Health, Sozial‐ und Präventivmedizin Medizinische Fakultät Mannheim, Universität Heidelberg Mannheim
| | - Joachim E. Fischer
- Mannheimer Institut für Public Health, Sozial‐ und Präventivmedizin Medizinische Fakultät Mannheim, Universität Heidelberg Mannheim
| | - Sergij Goerdt
- Klinik für Dermatologie Venerologie und Allergologie Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg Mannheim
| | - Wiebke K. Peitsch
- Klinik für Dermatologie Venerologie und Allergologie Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg Mannheim
- Klinik für Dermatologie und Phlebologie Vivantes Klinikum im Friedrichshain Berlin
| |
Collapse
|
20
|
Zweegers J, Roosenboom B, van de Kerkhof P, van den Reek J, Otero M, Atalay S, Kuijpers A, Koetsier M, Arnold W, Berends M, Weppner-Parren L, Bijen M, Njoo M, Mommers J, van Lümig P, Driessen R, Kievit W, de Jong E. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort. Br J Dermatol 2016; 176:786-793. [DOI: 10.1111/bjd.14888] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/15/2016] [Indexed: 01/24/2023]
Affiliation(s)
- J. Zweegers
- Department of Dermatology; Radboud University Medical Center; Nijmegen the Netherlands
| | - B. Roosenboom
- Department of Dermatology; Radboud University Medical Center; Nijmegen the Netherlands
| | - P.C.M. van de Kerkhof
- Department of Dermatology; Radboud University Medical Center; Nijmegen the Netherlands
| | - J.M.P.A. van den Reek
- Department of Dermatology; Radboud University Medical Center; Nijmegen the Netherlands
| | - M.E. Otero
- Department of Dermatology; Radboud University Medical Center; Nijmegen the Netherlands
| | - S. Atalay
- Department of Dermatology; Radboud University Medical Center; Nijmegen the Netherlands
| | | | | | - W.P. Arnold
- Ziekenhuis Gelderse Vallei; Ede the Netherlands
| | - M.A. Berends
- Slingeland Ziekenhuis; Doetinchem the Netherlands
| | | | - M. Bijen
- Ziekenhuisgroep Twente; Almelo/Hengelo the Netherlands
| | - M.D. Njoo
- Ziekenhuisgroep Twente; Almelo/Hengelo the Netherlands
| | | | - P.P.M. van Lümig
- Department of Dermatology; Radboud University Medical Center; Nijmegen the Netherlands
| | - R.J.B. Driessen
- Department of Dermatology; Radboud University Medical Center; Nijmegen the Netherlands
| | - W. Kievit
- Department of Epidemiology, Biostatistics and Health Technology Assessment; Radboud University Medical Center; Nijmegen the Netherlands
| | - E.M.G.J. de Jong
- Department of Dermatology; Radboud University Medical Center; Nijmegen the Netherlands
- Radboud University Nijmegen; Nijmegen the Netherlands
| |
Collapse
|
21
|
Dapavo P, Vujic I, Fierro MT, Quaglino P, Sanlorenzo M. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol 2016; 75:736-739. [PMID: 27473452 DOI: 10.1016/j.jaad.2016.04.068] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Revised: 03/28/2016] [Accepted: 04/25/2016] [Indexed: 12/30/2022]
Abstract
BACKGROUND The infliximab originator's patent recently expired, leading to the production of biosimilar versions of the drug. The biosimilars' efficacy was not tested on patients with psoriasis but most regulatory authorities approved their use in psoriasis because of an extrapolation of data from studies conducted in other diseases. OBJECTIVE We sought to describe the use of the infliximab biosimilar (Remsima; CT-P13) in patients with psoriasis. METHODS Objective (Psoriasis Area and Severity Index) and subjective (visual analog pain scale) measurements of disease activity were collected in 2 cohorts of patients with moderate to severe plaque psoriasis: cohort 1 patients switched from the infliximab originator to the infliximab biosimilar; and cohort 2 patients were infliximab-naïve and started on the infliximab biosimilar. RESULTS We observed no changes of Psoriasis Area and Severity Index and visual analog pain scale scores in 30 patients who switched from the infliximab originator to the biosimilar. Four of 5 infliximab-naïve patients who started infliximab biosimilar treatment achieved 75% improvement or better from baseline Psoriasis Area and Severity Index score at the end of the induction phase. LIMITATIONS Number of patients and length of follow-up was limited. CONCLUSIONS Patients with psoriasis taking infliximab originator treatment can switch to the infliximab biosimilar without experiencing a significant change in clinical response or additional adverse events. The use of the infliximab biosimilar could reduce the growing pressure on health care budgets.
Collapse
Affiliation(s)
- Paolo Dapavo
- Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy
| | - Igor Vujic
- Department of Dermatology, Rudolfstiftung Hospital, Academic Teaching Hospital, Medical University Vienna, Vienna, Austria; School of Medicine, Sigmund Freud University, Vienna, Austria
| | - Maria Teresa Fierro
- Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy
| | - Pietro Quaglino
- Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy
| | - Martina Sanlorenzo
- Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
| |
Collapse
|
22
|
Zweegers J, van den Reek J, van de Kerkhof P, Otero M, Kuijpers A, Koetsier M, Arnold W, Berends M, Weppner-Parren L, Ossenkoppele P, Njoo M, Mommers J, van Lümig P, Driessen R, Kievit W, de Jong E. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-t. Br J Dermatol 2016; 175:340-7. [DOI: 10.1111/bjd.14552] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/19/2016] [Indexed: 12/27/2022]
Affiliation(s)
- J. Zweegers
- Department of Dermatology; Biostatistics and Health Technology Assessment; Radboud University Medical Center; Nijmegen the Netherlands
| | - J.M.P.A. van den Reek
- Department of Dermatology; Biostatistics and Health Technology Assessment; Radboud University Medical Center; Nijmegen the Netherlands
| | - P.C.M. van de Kerkhof
- Department of Dermatology; Biostatistics and Health Technology Assessment; Radboud University Medical Center; Nijmegen the Netherlands
| | - M.E. Otero
- Department of Dermatology; Biostatistics and Health Technology Assessment; Radboud University Medical Center; Nijmegen the Netherlands
| | | | | | - W.P. Arnold
- Ziekenhuis Gelderse Vallei; Ede the Netherlands
| | | | | | | | - M.D. Njoo
- Ziekenhuisgroep Twente; Almelo Hengelo the Netherlands
| | | | - P.P.M. van Lümig
- Department of Dermatology; Biostatistics and Health Technology Assessment; Radboud University Medical Center; Nijmegen the Netherlands
| | - R.J.B. Driessen
- Department of Dermatology; Biostatistics and Health Technology Assessment; Radboud University Medical Center; Nijmegen the Netherlands
| | - W. Kievit
- Department of Epidemiology; Biostatistics and Health Technology Assessment; Radboud University Medical Center; Nijmegen the Netherlands
| | - E.M.G.J. de Jong
- Department of Dermatology; Biostatistics and Health Technology Assessment; Radboud University Medical Center; Nijmegen the Netherlands
- Radboud University; Nijmegen the Netherlands
| |
Collapse
|
23
|
Magis Q, Jullien D, Gaudy-Marqueste C, Baumstark K, Viguier M, Bachelez H, Guibal F, Delaporte E, Karimova E, Montaudié H, Boye T, Aubin F, Beylot-Barry M, Richard MA. Predictors of long-term drug survival for infliximab in psoriasis. J Eur Acad Dermatol Venereol 2016; 31:96-101. [DOI: 10.1111/jdv.13747] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Accepted: 03/25/2016] [Indexed: 01/24/2023]
Affiliation(s)
- Q. Magis
- Department of Dermatology; Hôpital Timone; Assistance Publique des Hôpitaux de Marseille; UMR 911; INSERM CRO2; “Centre de recherche en oncologie biologique et onco phamacologie”; Aix-Marseille University; Marseille France
| | - D. Jullien
- Department of Dermatology Hôpital Edouard Herriot; University Claude Bernard Lyon-1; University of Lyon; Lyon France
| | - C. Gaudy-Marqueste
- Department of Dermatology; Hôpital Timone; Assistance Publique des Hôpitaux de Marseille; UMR 911; INSERM CRO2; “Centre de recherche en oncologie biologique et onco phamacologie”; Aix-Marseille University; Marseille France
| | - K. Baumstark
- Clinical Research Platform; Assistance Publique des Hôpitaux de Marseille; EA 3279 “Qualité de vie et maladies chroniques”; Aix-Marseille University; Marseille France
| | - M. Viguier
- Department of Dermatology; AP-HP Hôpital Saint Louis; University Paris Diderot; Sorbonne Paris Cité; Paris France
| | - H. Bachelez
- Department of Dermatology; AP-HP Hôpital Saint Louis; University Paris Diderot; Sorbonne Paris Cité; Paris France
| | - F. Guibal
- Department of Dermatology; AP-HP Hôpital Saint Louis; University Paris Diderot; Sorbonne Paris Cité; Paris France
| | | | | | | | - T. Boye
- Hôpital d'instruction des armées St Anne; Toulon France
| | - F. Aubin
- Regional University Hospital Hôpital Jean Minjoz; Besançon France
| | - M. Beylot-Barry
- Department of Dermatology; Hôpital Saint-André; University of Bordeaux; Bordeaux France
| | - M.-A. Richard
- Department of Dermatology; Hôpital Timone; Assistance Publique des Hôpitaux de Marseille; UMR 911; INSERM CRO2; “Centre de recherche en oncologie biologique et onco phamacologie”; Aix-Marseille University; Marseille France
| | | |
Collapse
|
24
|
Torii H, Terui T, Matsukawa M, Takesaki K, Ohtsuki M, Nakagawa H. Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective post-marketing surveillance. J Dermatol 2015; 43:767-78. [DOI: 10.1111/1346-8138.13214] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2015] [Accepted: 10/12/2015] [Indexed: 11/28/2022]
Affiliation(s)
- Hideshi Torii
- Division of Dermatology; Tokyo Yamate Medical Center; Tokyo Japan
| | - Tadashi Terui
- Department of Dermatology; Nihon University School of Medicine; Tokyo Japan
| | - Miyuki Matsukawa
- Pharmacovigilance and Quality Assurance Division; Mitsubishi Tanabe Pharma Corporation; Osaka Japan
| | - Kazumi Takesaki
- Pharmacovigilance and Quality Assurance Division; Mitsubishi Tanabe Pharma Corporation; Osaka Japan
| | - Mamitaro Ohtsuki
- Department of Dermatology; Jichi Medical University; Shimotsuke Japan
| | - Hidemi Nakagawa
- Department of Dermatology; The Jikei University School of Medicine; Tokyo Japan
| | | |
Collapse
|